The JAK2V617F mutation commonly found in myeloproliferative neoplasms (MPNs) induces constitutive phosphorylation/activation of the signal transducer and activator of transcription 3 (Stat3). However, the contribution of Stat3 in MPN evoked by JAK2V617F remains unknown. To determine the role of Stat3 in JAK2V617F-induced MPN, we generated Stat3-deficient Jak2V617F-expressing mice. Whereas expression of Jak2V617F resulted in a polycythemia vera-like disease characterized by increased red blood cells (RBCs), hematocrit, neutrophils and platelets in the peripheral blood of Jak2V617F knock-in mice, deletion of Stat3 slightly reduced RBC and hematocrit parameters and modestly increased platelet numbers in Jak2V617F knock-in mice. Moreover, deletion of Stat3 significantly increased the neutrophil counts/percentages and markedly reduced the survival of mice expressing Jak2V617F. These phenotypic manifestations were reproduced upon bone marrow (BM) transplantation into wild-type animals. Flow cytometric analysis showed increased hematopoietic stem cell and granulocyte-macrophage progenitor populations in the BM and spleens of Stat3-deficient Jak2V617F mice. Stat3 deficiency also caused a marked expansion of Gr-1 + /Mac-1 + myeloid cells in Jak2V617F knock-in mice. Histopathologic analysis revealed marked increase in granulocytes in the BM, spleens and livers of Stat3-deficient Jak2V617F-expressing mice. Together, these results suggest that deletion of Stat3 increases the severity of MPN induced by Jak2V617F.
INTRODUCTION
The JAK2V617F mutation has been found in most patients with Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) including polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). [1] [2] [3] [4] [5] Expression of JAK2V617F results in constitutive activation of the JAK2 tyrosine kinase and its downstream signaling pathways, 1, 2, 6 and confers cytokine hypersensitivity to hematopoietic cells and progenitors. 1, 2 Several studies using bone marrow (BM) transplantation, transgenic and knock-in mouse models of Jak2V617F have confirmed a pathogenic role for JAK2V617F mutation in MPNs, [6] [7] [8] [9] [10] [11] [12] [13] but how JAK2V617F mediates hematopoietic transformation/ MPNs remains poorly understood. Unraveling the contribution of signaling pathways downstream of JAK2V617F in MPNs will improve our understanding of the pathogenesis of MPNs and lead to new therapeutic strategies for MPNs.
Several members of the signal transducer and activator of transcription (Stat) family proteins including Stat1, Stat3 and Stat5 are constitutively phosphorylated/activated in MPN cells expressing JAK2V617F. 1, 2, 14, 15 We and other groups have shown previously that Stat5 is critical for Jak2V617F-evoked PV disease in mice. 16, 17 Recently, it has been shown that Stat1 promotes megakaryopoiesis and has a role in induction of ET-like phenotype in a mouse model of Jak2V617F. 18 However, the role of Stat3 in MPN mediated by Jak2V617F remains unknown.
Stat3 is an important signaling molecule that is phosphorylated/ activated in response to a variety of cytokines including interleukin-6 (IL-6), IL-11 and granulocyte-colony stimulating factor (G-CSF). 19 It has been suggested that Stat3 serves as a negative regulator of granulopoiesis and positive regulator of B lymphopoiesis. 20, 21 It also has been reported that Stat3-deficient mice exhibit mitochondrial dysfunction and defects in hematopoietic stem cell (HSC) and progenitor function. 22 Constitutive activation of Stat3 has been observed in various human malignancies. 23 Although Stat3 has a tumor-promoting role in some malignancies, such as in pancreatic tumorigenesis and myeloid neoplasms induced by KrasG12D 24, 25 and in gastric cancer caused by the Helicobacter pylori infection, 26 other studies also have found a tumor suppressive function of Stat3 in certain malignancies. For instance, Stat3 negatively regulates BRAFV600Einduced thyroid tumorigenesis 27 or suppresses PTEN loss-induced glioblastoma. 28 Thus, Stat3 can positively or negatively regulate cell growth and tumor progression. Here, we sought to determine the role of Stat3 in JAK2V617F-evoked MPN using conditional Stat3 knockout (Stat3 floxed) and Jak2V617F knock-in mice. Our results show that deletion of Stat3 increases neutrophil counts in the peripheral blood and enhances expansion of hematopoietic progenitors and myeloid precursor cells in the BM and spleens of Jak2V617F knock-in mice. Furthermore, deletion of Stat3 markedly reduces the survival in a Jak2V617F knock-in mouse model of MPN. Taken together, these results suggest a negative role for Stat3 in Jak2V617F-induced MPN.
MATERIALS AND METHODS Mice
Conditional Jak2V617F knock-in 6 and floxed Stat3 (Stat3fl/fl) mice 29 have been described previously. MxCre mice 30 (purchased from the Jackson Laboratory, Bar Harbor, ME, USA) were crossed with Jak2V617F and Stat3fl/fl mice to generate Jak2V617F-expressing (MxCre;V617F/+), Stat3deficient (MxCre;Stat3fl/fl) and Stat3-deficient Jak2V617F-expressing (MxCre;V617F/+;Stat3fl/fl) mice. Mice were administrated with two doses of 200 μg polyinosine-polycytosine (pI-pC, GE Healthcare, Piscataway, NJ, USA) by intraperitoneal injection to induce Cre expression. All animal studies were approved by the Institutional Animal Care and Use Committee of SUNY Upstate Medical University.
Blood and tissue analyses
Blood was collected from tail vein and complete blood counts were measured on Hemavet 950FS (Drew Scientific, Dallas, TX, USA). Mouse tissue specimens (femurs, spleens and livers) were fixed in 10% neutral buffered formalin and embedded in paraffin. Tissue sections (4 μm) were then stained with hematoxylin and eosin.
Flow cytometry
Single-cell suspensions from BM and spleens were prepared and stained for 20 min on ice with either allophycocyanin-or phycoerythrinconjugated monoclonal antibodies against Ter119, CD71, CD41, CD61, Mac-1, Gr-1, B220 or Thy-1. For stem cell/progenitor analysis, BM or spleen cells were stained with antibodies against lineage (Lin) markers (CD3, CD4, CD8α, CD19, B220, Gr-1, Ter119 and IL-7R (CD127) and c-Kit, Sca1, Flk2 (CD135), CD34, CD16/32 (FcγRII/III) for 60 min on ice. All flow cytometry antibodies were purchased from eBioscience or BioLegend (San Diego, CA, USA). For cell cycle analysis, Lin-negative cells were first enriched by magnetic-activated cell sorting (Miltenyi Biotech, Auburn, CA, USA) and then stained with monoclonal antibodies against Lin markers, c-Kit and Sca1 along with Hoechst 33342 (Sigma-Aldrich, St. Louis, MO, USA) and Pyronin Y (Sigma-Aldrich). Flow cytometry was performed with an LSRII flow cytometer (BD Biosciences, San Diego, CA, USA) and analyzed using FlowJo software (TreeStar, Ashland, OR, USA).
Colony-forming assays BM (2 × 10 4 ) or spleen (1 × 10 5 ) cells were plated in duplicate in methylcellulose medium M3434 (Stem Cell Technologies, Vancouver, BC, Canada) containing cytokines. Burst-forming units-erythroid, colonyforming units-granulocyte-macrophage and CFU-granulocyte, erythrocyte, macrophage, and megakaryocyte colonies were scored on day 7. To detect Erythropoietin (Epo)-dependent/independent colony-forming unit-erythroid (CFU-E) colonies, BM or spleen cells (1 × 10 5 ) were seeded in duplicate in methylcellulose medium M3234 (Stem Cell Technologies) in the presence or absence of Epo (3 U/ml). CFU-E colonies were counted after 2 days by staining with benzidine solution (Sigma-Aldrich).
BM transplantation assay
Total BM cells from control, MxCre;V617F/+ or MxCre;V617F/+;Stat3fl/fl mice were harvested 2 weeks after pI-pC induction. BM cells (1 × 10 6 ) were transplanted by retro-orbital injection into lethally irradiated (2 × 550 cGy) C57BL/6 recipient mice. Mice were maintained on acidified water.
Quantitative real-time PCR
Total RNA was extracted from multi-potent progenitors (MPP) from control, MxCre;V617F/+ and MxCre;V617F/+;Stat3fl/fl mice using RNeasy Mini Kit (Qiagen, Valencia, CA, USA) and reverse transcribed by using QuantiTect Reverse Transcription kit (Qiagen). Quantitative real-time PCR was carried out with SYBR Green PCR master mix (Roche Diagnostics, Indianapolis, IN, USA) on a LightCycler 480 (Roche Applied Science, Indianapolis, IN, USA) using the following primers:
5′-AACGACCTGCAGCAATACCA-3′ and 5′-AAGGTGATCAGGTGCAGCTC-3′ for Stat3, 5′-AGCTCCAAAAGCGAGTACCA-3′ and 5′-TGACGCTCAACGTGAAG AAG-3′ for SOCS3, 5′-CCTGTGCCAGTATGATGTGG-3′ and 5′-CAGGGTCACAC TCGTCAATG-3′ for Notch1, 5′-ATCGCTGCAGCTTCCTATGT-3′ and 5′-AGTCAT GCTTTCCCGTGTTC-3′ for C/EBP-β, 5′-CGCCGCTAGAGGTGAAATTC-3′ and 5′-TTGGCAAATGCTTTCGCTC-3′ for 18S. The data were normalized to 18S and fold change in gene expression was determined by the ΔΔCt method.
Statistical analysis
Results are presented as mean ± s.e.m., and statistical significance was determined by one-way analysis of variance or Student's t-test using Prism Version 5 software (GraphPad, San Diego, CA, USA). Po0.05 was considered statistically significant.
RESULTS
To determine the role of Stat3 in Jak2V617F-induced MPNs, we crossed our conditional Jak2V617F knock-in mice 6 with Stat3floxed (Stat3fl/fl) mice 29 and MxCre transgenic mice, 30 Figure 1j ). Spleen size/weight in MxCre;V617F/+; Stat3fl/fl mice was smaller than in MxCre;V617F/+ mice, but was significantly larger than in control animals ( Figure 1j ).
Histopathologic analyses of the BM sections from MxCre;Stat3fl/ fl mice showed increased, predominantly mature, granulocytic cells (Figure 2a ). BM of MxCre;V617F/+ mice showed trilineage hyperplasia with increased immature erythroid and myeloid precursors and increased megakaryocytes (Figure 2a ). BM of MxCre;V617F/+;Stat3fl/fl mice showed markedly increased immature myeloid (granulocytic) precursors and megakaryocytes but less erythroid precursors (Figure 2a ). Spleen sections from MxCre; Stat3fl/fl mice showed red pulp with increased immature and mature granulocytes and also maturing erythroid precursors ( Figure 2b ). Spleen sections from MxCre;V617F/+ mice showed attenuation of white pulp and expansion of red pulp with clusters of immature erythroid precursors and dysplastic megakaryocytes ( (Figures 3a and b ). Together, these results suggest that the deletion of Stat3 enhances granulocytic/megakaryocytic cell expansion, decreases erythropoiesis to some extent and shortens the survival of Jak2V617F mice.
We further determined the effects of Stat3 ablation on HSCs and progenitor compartments in mice expressing Jak2V617F by flow cytometric analysis. Deletion of Stat3 in Jak2V617F knock-in mice significantly increased the HSC-enriched LSK (Lin -Sca1 + c-kit + ) compartment and its subsets including long-term HSC (Lin -Sca1 + ckit + CD34 -CD135 -), short-term HSC (Lin -Sca1 + c-kit + CD34 + CD135 -), and multi-potent progenitors (MPP; Lin -Sca1 + c-kit + CD34 + CD135 + ) in the BM and spleens. Specifically, the increases in LSK, long-term HSC, short-term HSC and MPP populations were much greater in the spleens than in the BM of Stat3-deleted Jak2V617F mice (Figures 4a and b) . Flow cytometric analysis also revealed marked expansion of granulocyte-macrophage progenitors (GMP; Lin -Sca1c-kit + CD34 + FcγRII/III high ) in both BM and spleens upon concomitant deletion of Stat3 in mice expressing Jak2V617F ( Figures 4c and d) . The megakaryocyte/erythroid progenitor compartment (Lin -Sca1c-kit + CD34 -FcγRII/III -) was reduced in the BM of MxCre;V617F/+;Stat3fl/fl mice compared with MxCre;V617F/ + mice. However, no significant difference in megakaryocyte/ erythroid progenitor compartment was observed in the spleens between MxCre;V617F/+ and MxCre;V617F/+;Stat3fl/fl mice, both of which had a significantly higher (four-to five-fold) megakaryocyte/erythroid progenitor compartment population than in control mice (Figures 4c and d) . LSK, long-term HSC, short-term HSC and MPP populations in the BM of Stat3-deficient (MxCre; Stat3fl/fl) mice were comparable to those in control animals ( Supplementary Figure 1a ). However, there was a trend of increased LSK, long-term HSC, short-term HSC and MPP populations in the spleens of MxCre;Stat3fl/fl mice ( Supplementary Figure 1a ). GMP and megakaryocyte/erythroid progenitor compartment populations were also significantly increased in the spleens of MxCre;Stat3fl/fl mice compared with control animals (Supplementary Figure 1b) .
Next, we preformed progenitor colony assays to evaluate the effects of Stat3 deletion on hematopoietic progenitor compartments of Jak2V617F mice. Although there was no significant difference in Burst-forming units-erythroid and colony-forming units-granulocyte-macrophage colonies in the BM among control, MxCre;V617F/+ and MxCre;V617F/+;Stat3fl/fl mice at 2-3 weeks after pI-pC induction (Figure 4e Figure 4g ). However, the numbers of CFU-E colonies in the presence of Epo in the spleens of MxCre;V617F/+;Stat3fl/fl mice were comparable to that observed in the spleens of MxCre;V617F/+ mice (Figure 4h ). Epo-independent CFU-E colonies, a hallmark feature of PV, 31 was also observed in the spleens of both MxCre; V617F/+ and MxCre;V617F/+;Stat3fl/fl mice (Figure 4i ). However, there was a modest (not statistically significant) decrease in Epo-independent CFU-E colony formation in the spleens of MxCre; V617F/+;Stat3fl/fl mice compared with MxCre;V617F/+ mice (Figure 4i ). Overall, the deletion of Stat3 in Jak2V617F-expressing mice was associated with an expansion of HSC and GMP compartments and a trend toward decreased erythroid progenitors/precursors. To address why deletion of Stat3 causes expansion of HSC compartment in mice expressing Jak2V617F, we performed cell cycle analysis on BM LSK cells from control, MxCre;V617F/+ and MxCre;V617F/+;Stat3fl/fl mice using Pyronin Y/Hoechst 33342 staining. Compared with control LSK cells, significantly fewer numbers of Jak2V617F-expressing LSK cells were in the quiescent G0 phase, with a higher proportion in the G 1 and S/G 2 /M phases (Figures 5a and b ). Concurrent deletion of Stat3 further enhanced Jak2V617F-evoked cell cycle entry of LSK cells (Figures 5a and b) . These results suggest that deletion of Stat3 leads to increased proliferation of HSC pool in mice expressing Jak2V617F.
To assess whether the observed effects of Stat3 deficiency on Jak2V617F-induced MPN were cell autonomous, we transplanted BM cells from pI-pC-induced control, MxCre;V617F/+ and MxCre; V617F/+;Stat3fl/fl mice into lethally irradiated C57BL/6 wild-type recipients as outlined in Figure 6a . Recipient animals were maintained for 8 weeks after transplantation. Similar to the primary Stat3-deficient Jak2V617F mice, recipients of the BM cells from MxCre;V617F/+;Stat3fl/fl mice exhibited significantly increased percentage of neutrophils and decreased percentage of lymphocytes in the peripheral blood (Figure 6b ), and markedly elevated Gr-1 + /Mac-1 + populations in both BM and spleens (Figures 6c and d) . Compared with control BM recipients, transplanted animals receiving BM cells from either MxCre; V617F/+ or MxCre;V617F/+;Stat3fl/fl mice exhibited increased numbers of RBC in their peripheral blood and increased percentage of erythroid precursors (CD71 + Ter119 + , CD71 + ) in their BM and/or spleens (Figures 6b and d) , indicating the presence of PV-like MPN in mice reconstituted with MxCre;V617F/+ or MxCre;V617F/+;Stat3fl/fl BM cells. However, the RBC counts were slightly lower and the platelet counts were slightly higher in the recipients of MxCre;V617F/+;Stat3fl/fl BM cells compared with the transplanted animals receiving MxCre;V617F/+ BM cells (Figure 6b ). Recipients of MxCre;V617F/+;Stat3fl/fl mice BM cells also exhibited a significantly increased GMP population and a trend of increased LSK cells in the BM (Figure 6e ). Together, these results suggest that the effects of Stat3 deficiency on Jak2V617Finduced MPN are cell autonomous.
As homozygous Stat3 deletion led to early deaths in mice expressing Jak2V617F, we also assessed the effects of heterozygous Stat3 deletion on Jak2V617F-induced MPN. As expected, the expression of Stat3 in the BM of MxCre;V617F/+;Stat3fl/+ mice was almost half of those in control or MxCre;V617F/+ mice after pI-pC induction ( Supplementary Figure 2a ). No early death was found in induced MxCre;V617F/+;Stat3fl/+ mice, which had a similar lifespan as Jak2V617F knock-in mice (data not shown). All MxCre;V617F/+;Stat3fl/+ mice developed a PV-like MPN with comparable blood parameters and splenomegaly to those observed in Jak2V617F knock-in mice after pI-pC injection ( Supplementary Figures 2b-g) . There was also no significant difference in splenic Epo-independent CFU-E formation between MxCre;V617F/+;Stat3fl/+ and MxCre;V617F/+ mice ( Supplementary  Figure 2h ). Furthermore, flow cytometric analysis showed no significant differences in myeloid, erythroid and megakaryocytic precursors, as well as B-cell and T-cell populations between MxCre; V617F/+;Stat3fl/+ and MxCre;V617F/+ mice ( Supplementary  Figures 3a and b) . Altogether, these data indicate that heterozygous deletion of Stat3 has no significant effect on Jak2V617Finduced MPN.
To determine whether the deficiency of Stat3 had any effect on signaling by other Stat proteins, we assessed the phosphorylation and expression of Stat5 and Stat1 proteins in the BM of control, MxCre;V617F/+ and MxCre;V617F/+;Stat3fl/fl mice by immunoblotting. Deletion of Stat3 did not cause any significant change in phosphorylation or expression of Stat5 in Jak2V617F knock-in mice BM (Figure 7a ). However, phosphorylation and expression of Stat1 protein was significantly increased upon deletion of Stat3 in Jak2V617F knock-in mice BM (Figure 7a ). We also assessed the expression levels of suppressor of cytokine signaling 3 (SOCS3) by immunoblotting since SOCS3 was found upregulated in JAK2V617F-positive MPN patient cells 32 and SOCS3 was shown to inversely regulate the activation of Stat1 and Stat3 in response to G-CSF, interferon-γ and IL-6. 20, 33, 34 We observed increased SOCS3 protein expression in the BM of MxCre;V617F/+ mice (Figure 7a ). Deletion of Stat3 significantly inhibited the SOCS3 protein expression in the BM of Jak2V617F mice (Figure 7a ).
To gain further insights into the mechanism by which Stat3 deficiency increases the myeloid cell expansion and severity of MPN phenotype in Jak2V617F knock-in mice, we analyzed the expression levels of specific genes in MPP from control, MxCre; V617F/+ and MxCre;V617F/+;Stat3fl/fl mice using quantitative realtime PCR. The expression of Stat3 mRNA was almost undetectable in the MPP populations of MxCre;V617F/+;Stat3fl/fl mice, suggesting efficient deletion of Stat3 in the hematopoietic progenitors of these mice (Figure 7b ). The expression of Notch1 was significantly downregulated in MPP populations from MxCre;V617F/+;Stat3fl/fl mice compared with those in control and MxCre;V617F/+ mice (Figure 7b ). Similar to SOCS3 protein expression, SOCS3 mRNA expression was also significantly reduced in MPP from MxCre; V617F/+;Stat3fl/fl mice compared with those in MxCre;V617F/+ mice (Figure 7b ). In contrast, expression of C/EBP-β was found significantly elevated in MPP populations from MxCre;V617F/+; Stat3fl/fl mice compared with those in control and MxCre;V617F/+ mice (Figure 7b ). There was also a modest increase in C/EBP-α expression in MPP from MxCre;V617F/+;Stat3fl/fl mice (data not shown). These results suggest that decreased expression of Notch1 and SOCS3 and increased expression of C/EBP-β induced by Stat3 deletion may contribute to the myeloid cell expansion in Stat3-deficient Jak2V617F knock-in mice.
DISCUSSION
Constitutive phosphorylation/activation of Stat3 has been frequently observed in MPNs. 15, 35 However, the precise role of Stat3 in the pathogenesis of MPNs remains unclear. In this study, we examined the role of Stat3 in the development of MPN using conditional Jak2V617F knock-in and Stat3-deficient mice. We found that ablation of Stat3 does not prevent the development of MPN, rather augments the myeloid cell expansion and decreases the survival in a Jak2V617F knock-in mouse model of MPN.
Stat3 can be activated by oncogenic tyrosine kinases (such as JAK2V617F), 15, 35, 36 by autocrine production of IL-6 37 or through activating somatic Stat3 mutations. 38 Persistent activation of Stat3 has been observed in a variety of human malignancies. In some cases, such as in KrasG12D-induced pancreatic and myeloid malignancies, Stat3 promotes tumorigenesis. 24, 25 In other malignancies, such as BRAFV600E-induced thyroid tumorigenesis and PTEN loss-induced glioblastomas, Stat3 functions as a tumor suppressor. 27, 28 In this study, we have found that Stat3 is not essential for development of PV-like MPN in mice induced by Jak2V617F. We have observed that deletion of Stat3 rather enhances the severity of MPN induced by Jak2V617F, suggesting a negative role of Stat3 in Jak2V617F-induced PV. Stat3 is also found to be constitutively phosphorylated/activated in MF. 15, 35 Since all Role of Stat3 in Jak2V671F-induced MPN D Yan et al Stat3-deleted Jak2V617F (MxCre;V617F/+;Stat3fl/fl) mice died within 4 weeks after pI-pC induction (Figure 1b ), we were unable to assess the contribution of Stat3 in the development of MF evoked by Jak2V617F. Future studies will determine whether Stat3 is required for the pathogenesis of MF and whether targeting of Stat3 could be beneficial for treatment of MF. Previous reports have shown that Stat3 positively regulates B-cell development, 21 and negatively regulates granulopoiesis. 20 Indeed, we observed significantly increased numbers of neutrophils in the peripheral blood and increased percentages of Gr-1 +/Mac-1+ myeloid precursors in the BM and spleens of Stat3deficient Jak2V617F knock-in mice (Figures 1f, 3a and b ). We also observed significantly increased percentages of GMP populations in the BM and spleens of Stat3-deficient Jak2V617F mice compared with control or Jak2V617F mice (Figures 4c and d) . Furthermore, the HSC compartment was significantly expanded in the BM and spleens of Stat3-deficient Jak2V617F mice (Figures 4a  and b ). Deficiency of Stat3 alone did not cause a significant expansion of HSC and GMP in the BM but splenic HSC and GMP populations were expanded upon Stat3 deletion ( Supplementary  Figures 1a and b) . However, the expansion of HSC and GMP in the BM and spleens of Stat3-deficient Jak2V617F mice was significantly greater than that observed in mice with Jak2V617F expression or Stat3 deletion alone (Figures 4b and d and Supplementary Figures 1a and b) . Cell cycle analysis revealed that Jak2V617F expression increased the cycling of LSK cells ( Figures 5a and b) . Deletion of Stat3 further enhanced the cycling of Jak2V617F-expressing LSK cells (Figures 5a and b) . Thus, increased number of HSC/progenitors in Stat3-deficient Jak2V617F mice could be due to increased proliferation of HSCs induced by Stat3 deficiency. The phenotypic changes observed in primary Stat3-deficient Jak2V617F mice were reproduced in recipient animals that were transplanted with BM from Stat3-deficient Jak2V617F mice ( Figure 6 ). This indicates that the observed effects of Stat3 deficiency in Jak2V617F knock-in mice were cell autonomous.
We observed a compensatory increase in phosphorylation of Stat1 but not Stat5 in Stat3-deficient Jak2V617F mice BM (Figure 7a) , consistent with the previous reports that Stat1 and Stat3 oppose each other's activation in response to G-CSF, interferon-γ and IL-6. 20, 33, 34 Increased activation of Stat1 might be due to the decreased expression of SOCS3, which is a negative regulator of cytokine signaling, 39 and/or increased levels of cytokines, such as G-CSF, interferon-γ and IL-6, which can induce phosphorylation of Stat1. 19 Increased levels of SOCS3 expression was observed in granulocytes from JAK2V617F-positive MPN patients. 32 Moreover, SOCS3 protein was found to be hyperphosphorylated and stabilized by JAK2V617F. 40 We observed increased expression of SOCS3 mRNA and protein in Jak2V617F knock-in (MxCre;V617F/+) mice, and deletion of Stat3 significantly reduced the SOCS3 levels in Stat3-deficient Jak2V617F mice (MxCre;V617F/+;Stat3fl/fl; Figures 7a and b) . These data suggest that Stat3 is required for induction of SOCS3 in response to Jak2V617F. SOCS3 was shown to negatively regulate G-CSF receptor signaling, and mice deficient in SOCS3 exhibited increased granulopoiesis. 41, 42 Thus, it is plausible that decreased expression of SOCS3 in the absence of Stat3 may partially contribute to the increased granulopoiesis and compensatory increase in Stat1 phosphorylation in Stat3-deficient Jak2V617F mice. The loss of Stat1 was shown to reduce megakaryopoiesis and increase erythropoiesis in a transgenic Jak2V617F mouse model of MPN, although Stat1 was not essential for ET phenotype in this model. 18 Thus, the trend toward decreased erythropoiesis observed in Stat3-deleted Jak2V617F mice could also be partly due to a compensatory increase in Stat1 activation in these mice. In contrast, Stat5 ablation completely inhibited the PV phenotype in Jak2V617F knock-in and retroviral transduction/transplantation mouse models. 16, 17 Therefore, the roles and requirements for Stat1, Stat3 and Stat5 in MPNs are distinct.
We also found that Stat3 deficiency in Jak2V617F knock-in mice MPP resulted in significant reduction in Notch1 expression ( Figure 7b ). Notch signaling can have both oncogenic and tumor-suppressor functions. 43 A recent study has suggested a tumor-suppressor function of Notch1 in myeloid leukemia. 44 Deletion of Notch1 resulted in significant expansion of GMP population in mice. 44 The increase in myeloid cells and GMP populations observed in Stat3-deficient Jak2V617F mice could be in part due to the reduced Notch1 expression. We also observed marked increase in C/EBP-β and modest increase in C/EBP-α expression in the MPP from Stat3-deficient Jak2V617F mice (Figure 7b and data not shown). C/EBPs have an important role in granulopoiesis. 45 Mice deficient in C/EBP-α exhibit defects in granulopoieis, 46 whereas ectopic expression of C/EBP-β induces granulocytic differentiation. 47 Increased C/EBP-β and C/EBP-α expression induced by Stat3 deficiency may also contribute to the myeloid cell expansion observed in Stat3-deficient Jak2V617Fexpresssing mice.
In conclusion, our data show that Stat3 acts as a suppressor of Jak2V617F-induced MPN in mice. Several Stat3 inhibitors have been developed and currently undergoing pre-clinical and clinical testing for various human malignancies. As Stat3 can positively or negatively regulate tumorigenesis, its role in different cancer settings should be carefully examined before utilizing the Stat3 inhibitors. Further studies will determine whether Stat3 has a pathogenic role in human MPNs (PV, ET and MF) and whether inhibition of Stat3 has beneficial or adverse effects in human MPNs.
